The 30-share BSE Sensex was up 357.47 points at 57927.72
Posts in category Economic Times
Stock market update: Mining stocks up as market rises (01-08-2022)
The 30-share BSE Sensex was up 357.47 points at 57927.72
Buy Torrent Pharma, target price Rs 1750: Prabhudas Lilladher (01-08-2022)
Torrent Pharmaceuticals Ltd., incorporated in the year 1972, is a Large Cap company (having a market cap of Rs 51741.54 Crore) operating in Pharmaceuticals sector.
Share market update: Most active stocks on D-Street today in terms of volume (01-08-2022)
The NSE Nifty index was trading 117.1 points up at 17275.35
Avenue Supermart stock price up 1.22 per cent as Sensex climbs (01-08-2022)
As of 30-Jun-2022, promoters held 74.99 per cent stake in the company, while FIIs held 8.59 per cent and domestic institutional investors had 6.33 per cent.
Avenue Supermart stock price up 1.22 per cent as Sensex climbs (01-08-2022)
As of 30-Jun-2022, promoters held 74.99 per cent stake in the company, while FIIs held 8.59 per cent and domestic institutional investors had 6.33 per cent.
Buy Strides Pharma Science, target price Rs 402: ICICI Securities (01-08-2022)
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3026.83 Crore) operating in Pharmaceuticals sector.
Stock market update: Nifty Pharma index falls 0.26% in an upbeat market (01-08-2022)
The Nifty Pharma index was trading 0.26 per cent down at 12743.3.
Aurobindo Pharma shares up 1.02% as Nifty gains (01-08-2022)
A total of 325,466 shares changed hands on the counter till time (IST).
Stock market update: FMCG stocks up as market rises (01-08-2022)
The 30-share BSE Sensex was up 370.14 points at 57940.39
Brokerages see up to 20% upside in Cipla post Q1 results; time to buy? (01-08-2022)
Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.